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Abstract
Objectives: use  of  potent  antiplatelet  drugs  requires
evaluation of platelet function. While platelet function
in elective cases is usually assessed in a central labora-
tory  environment,  there  is  also  an  urgent  need  for
rapid perioperative point-of-care assessment. Recently,
multiple electrode platelet aggregometry has been de-
veloped and assumed to measure platelet function in-
dependent from platelet count. We tested the hypothe-
sis  that  results  of  multiple  electrode  platelet  aggre-
gometry are affected by platelet count, in particular if
platelet count is below normal range. 
Methods: Whole blood samples from 20 healthy volun-
teers were prepared containing platelet concentrations
of 50,000, 100,000, 150,000, 200,000, and 250,000 ﾵl-1
while maintaining hematocrit. Platelet aggregation was
induced by collagen, thrombin receptor activating pep-
tide  6  (tRaP-6),  adenosine-diphoshate  (adP),  and
arachidonic  acid,  respectively,  and  aggregation  was
measured by multiple electrode platelet aggregometry
(Multiplate™).
Results: Results of multiple electrode platelet aggre-
gometry significantly decreased in blood samples with
platelet count below normal range. compared to re-
sults measured in blood samples with platelet count
within normal range, aggregometry results decreased
by 18.4 % (p<0.001) and 37.2 % (p<0.001) in blood
samples with a platelet count of 100.000 and 50.000
ﾵl-1, respectively. on the other hand, large interindi-
vidual  variation  has  been  observed  and  some  blood
samples  showed  normal  results  even  with  platelet
counts of 50.000 ﾵl-1. 
Conclusion: the  results  obtained  with  Multiplate™
analyzer are influenced by platelet function as well as
platelet count thus displaying the overall platelet ag-
gregability within the blood sample rather than platelet
function alone.
Key words: Impedance aggregometry, Multiplate, plate  -
let count, thrombocytopenia, point-of-care testing
IntRoductIon
Intensified and combined antiplatelet therapy in cardi-
ology and cardiovascular surgery as well as peri-opera-
tive  disturbances  of  haemostasis  implicate  the  need
for rapid peri-operative monitoring of platelet func-
tion [1-3]. classical methods for assessment of platelet
function, such as born aggregometry or flow cytome-
try are time consuming and require preanalytical pro-
cessing of the blood sample. therefore, they are har-
bored in central laboratory environments and are of
little use during anaesthesia and surgery. Recently, mul-
tiple electrode platelet aggregometry has been intro-
duced  and  recommended  for  point-of-care  (Poc)
testing of platelet function [4]. 
based on impedance aggregometry, first described
by  cardinal  and  flower  [5],  the  multiple  electrode
platelet  aggregometry  (Multiplate™  analyzer,  dyn-
abyte medical, Munich, germany) [6, 7] acts by mea-
suring the time-related increase of impedance between
two electrodes as a result of platelet aggregation on
the  electrodes  following  pharmacological  activation.
toth  et  al.  evaluated  this  method  in  blood  samples
with a platelet count within normal range and reported
reliable detection of platelet inhibition evoked by dif-
ferent agents [7]. However, during major surgery, e.g.,
liver  transplantation  or  cardiaovascular  surgery,
platelet dysfunction and thrombocytopenia often co-
exist requiring assessment of platelet function. 
accordingly, we tested the null hypothesis that re-
sults of impedance aggregometry obtained by Multi-
pate™ analyzer are not influenced by platelet count.
MEtHods
the study was approved by the local ethic committee
and all subjects gave their written informed consent
before  participation.  twenty  healthy  volunteers  (13
male, 7 female) of caucasian origin without haemosta-
tic  disorders  and  free  of  medication  were  recruited
from students and faculty.
Venous blood was collected into heparinized tubes
(sarsted ag & co, n￼mbrecht, germany) via a large
diameter cannula (0.9 mm Id) inserted into a cubital
vein. 
MEasuREMEnts and PRocEduREs
Platelet  count,  haemoglobin  concentration,  and
haematocrit were measured by an automated hematol-
ogy analyzer (sysmex mo. KX-21n, norderstedt, ger-
many)  (normal  range  of  platelet  count:  150,000-
300,000 ﾵl-1). to obtain blood samples with adjusted
platelet count without change in haematocrit, half of
the originally sampled blood volume was centrifuged
at 2500 g for 15 min. afterwards plasma and red blood
Eur J Med Res (2010) 15: 214-219 ﾩ I. Holzapfel Publishers 2010
IMPact of PlatElEt count on REsults obtaInEd fRoM MultIPlE
ElEctRodE PlatElEt aggREgoMEtRy (MultIPlatE™)
a. a. Hanke1, K. Roberg4, E. Monaca2, t. sellmann2, c. f. Weber3, n. Rahe-Meyer1, K. g￶rlinger4
1Klinik f￼r an￤sthesiologie und Intensivmedizin, Medizinische Hochschule Hannover,
2Klinik f￼r an￤sthesiologie, universit￤tsklinikum d￼sseldorf,
3Klinik f￼r an￤sthesiologie, Intensivmedizin und schmerztherapie, J.-W. goethe universit￤tsklinikum frankfurt,
4Klinik f￼r an￤sthesiologie und Intensivmedizin, universit￤tsklinikum Essen, germany
5. Hanke_Umbruchvorlage  07.05.10  14:05  Seite 214cells were separated and platelet rich buffy coat was
discarded.  Red  blood  cells  and  platelet  poor  plasma
were then remixed at primary haematocrit to serve as
platelet  poor  blood  for  subsequent  dilutional  steps.
native blood was then mixed with platelet poor blood
to adjust blood samples to platelet counts of 50,000,
100,000, 150,000, 200,000, and 250,000 ﾵl-1, respec-
tively. due to variations in platelet count in our healthy
volunteers  platelet  concentrations  of  200,000  and
250,000  ﾵl-1 were  not  achieved  in  all  individuals
(50,000, 100,000, and 150,000 ﾵl-1: n = 20; 200,000 ﾵl-
1: n = 16; 250,000 ﾵl-1: n = 6).
Platelet aggregation was measured by Multiplate™
analyzer (dynabyte, Munich, germany) following acti-
vation with commercially available standard reagents
(dynabyte, Munich, germany). to test different path-
ways of platelet aggregation and their potential depen-
dence on platelet count, aggregation was stimulated 1)
via adenosine-diphosphate (adP) receptors by adP
(adP-test), 2) by arachidonic acid, the substrate of
cyclooxygenase (coX), which subsequently forms the
potent  platelet  activator  thromboxane  a2  (tXa2)
(asPI-test), 3) by collagen via the collagen receptor,
which leads to a release of endogenous arachidonic
acid  and  tXa2    (col-test),  and  4)  by  tRaP-6
(thrombin  receptor  activating  peptide  6)  via  the
thrombin  receptor  on  the  plateletsﾴ  surface  (tRaP-
test).
after  platelet  activation  Multiplate™  analyzer
records  impedance  between  two  electrodes  during  a
period  of  six  minutes  reflecting  platelet  aggregation
on the surface of the electrodes. the measuring cell
contains two pairs of electrodes to serve as an internal
control. Results are displayed as amplitude-time-curves
over six minutes assessing the following variables: ve-
locity  of  aggregation  (VEl,  the  maximum  slope  of
the curve), maximum aggregation (aggR, the maxi-
mum amplitude of the curve), and, most important,
the area under the curve (auc). auc is affected by
both velocity and maximum aggregation and is consid-
ered as the best parameter to reflect overall platelet ag-
gregation [6, 7]. auc is cE labelled and usually the
main variable used for treatment decisions while ve-
locity and maximum aggregation are used for research
only. a typical tracing is displayed in figure 1. Refer-
ence ranges for auc are displayed in figure 2.
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Fig. 2. Platelet aggregation area under the curve depends on platelet count. Results show a significant decrease in aggregation with
a platelet count below 150,000 ﾵl-1, irrespective of stimulant. Reference ranges for each activator are highlighted by light grey 
boxes. *are assigned with statistically significant different results as compared to the lower end of normal range (150,000 ﾵl-1).
Fig. 1. Example of a platelet aggregation curve. note that the
two aggregation curves which represent two parallel measure-
ments are almost superimposable. the most important para-
meter for aggregation is the area under the aggregation curve
(auc).
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data  are  expressed  as  means  (ﾱ  standard  deviation,
sd) or boxplots. for statistical analysis the statistical
Package for social sciences (sPss for Windows, 13.0,
sPss Inc., chicago, Il., usa) and graphPad Prism
(Version  4.02,  graphPad  software  Inc.,  san  diego,
ca., usa) were used. data were positively tested for
normal distribution and then analyzed using repeated
measures analysis of variance followed by a paired t-
test with bonferroni correction. an a-error p below
0.05 /n was considered to be statistically significant. 
REsults
compared to the minimum value of normal platelet
count (150,000 ﾵl-1) significantly decreased auc re-
sults were detected in blood samples with a platelet
count  of  50,000  ﾵl-1 for  all  activators  (adP,  asPI,
col,  tRaP).  furthermore,  adP,  asPI,  and  col
stimulation in blood samples with a platelet count of
100,000 ﾵl-1 also yielded diminished aggregation. no
differences in auc were found in blood samples with
different platelet counts within the normal range with
all activators (fig. 2).
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Table 1. frequency of measurements within the normal reference range depending on platelet count
Platelet count (µl-1) 50 100 150 200 250
adP 30%  35% 80% 81.3% 100%
(6/20) (9/20) (16/20) (13/16) (6/6)
asPI 30%  30% 65% 68.8% 83.3%
(6/20) (6/20) (13/20) (11/16) (5/6)
col 40%  50% 70% 75% 66.7%
(8/20) (10/20) (14/20) (12/16) (4/6)
tRaP 30%  50%  60%  68.8% 66.7%
(6/20) (10/20) (12/20) (11/16) (4/6)
overall 32.5% 43.8% 72%
(26/80) (35/80) (121/168)
Percentage of measurements within the normal reference range with the absolute number of measurements given in brackets.
Fig. 3. Velocity of platelet aggregation depends on platelet count. Results show a significant decrease in aggregation velocity
with a platelet concentration below 150,000 ﾵl-1 irrespective. * are assigned with statistically significant different results as com-
pared to the lower end of normal range (150,000 ﾵl-1).
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locity. compared to the minimum valueo fnormal
plate  let  count  (150,000  ﾵl-1)  at  a  platelet  count  of
50,000 ﾵl-1 significantly decreased results in aggrega-
tion velocity were measured for all stimulants (adP,
asPI, col, tRaP). In addition, aggregation velocity
after activation with adP, asPI, and col was also re-
duced  at a platelet count of 100,000 ﾵl-1. no differ-
ences  in  aggregation  velocity  were  found  within  the
normal range of platelet count for all stimulants (fig.
3).
by the same token, compared to the minimum val-
ue of normal platelet count (150,000 ﾵl-1) at a platelet
count of 50.000 ﾵl-1 significantly decreased results in
maximum aggregation were detected for all stimulants
(adP, asPI, col, tRaP). this could also be shown
for adP, asPI, and col activation at a platelet con-
centration  of  100,000  ﾵl-1.  no  differences  in  maxi-
mum aggregation were found within the normal range
of platelet count for all stimulants (fig. 4 ).
dIscussIon
avoidance of unneccessary blood transfusion and re-
duction of transfusion requirements are of great im-
portance  to  minimize  transfusion  related  adverse
events [8-11]. In most hospitals, intraoperative platelet
diagnostics are limited to platelet count, and efficacy
of  platelet  transfusion  is  assessed  by  an  increase  in
platelet count and “dryness” of the surgical field [1-3].
However,  in  patients  with  antiplatelet  therapy  after
percutaneous coronary artery interventions or chronic
medication  with  antiplatelet  drugs  platelet  count  is
within the normal range whereas platelet function is
compromised.  standard  laboratory  coagulation  para-
meters do not predict increased perioperative bleeding
in these patients [12]. furthermore, there is evidence
that platelet function is impaired by major surgery, e.g.,
during cardiopulmonary bypass [13, 14]. accordingly,
there is a need for peri-operative point of care (Poc)
platelet function testing to guide therapy in order to
reduce transfusion requirements, transfusion associat-
ed adverse events, and costs [4, 7, 15-21].
Multiple electrode platelet aggregometry is one of
the most recently developed methods for Poc mea-
surement of platelet function [6, 7]. toth et al. report-
ed  in  their  publication  that  results  obtained  by  the
Multiplate™  analyzer  reflect  platelet  inhibition  in-
duced by different agents and that these results were
independent of platelet count [7]. However, all sub-
jects involved in this study had a platelet count within
the normal range between 150,000 and 400,000 ﾵl-1.
therefore,  independence  from  platelet  count  of  re-
sults obtained by this Poc method has not really been
tested in this study. Moreover, our study shows clearly
that results obtained by impedance aggregometry  are
influenced  significantly  by  platelet  count  in  case  of
values below the normal range of 150,000 ﾵl-1 inde-
pendent from the used platelet activator. 
contrary  to  other  platelet  function  tests  such  as
born aggregometry, which uses platelet rich plasma,
Multiplate™  analyzer,  as  a  Poc  device,    assesses
whole blood. In our study, we maintained hematocrit
in  all  analysed  blood  samples  at  the  same  level  by
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Fig. 4. Maximum platelet aggregation depends on platelet count. Results show a significant decrease in maximum aggregation
with a platelet concentration below 150,000 ﾵl-1, irrespective of the stimulant. * are assigned with statistically significant differ-
ent results as compared to the lower end of normal range (150,000 ﾵl-1).
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ingly, our results should not be influenced by different
concentrations  of  coagulation  factors  and  cellular
blood elements besides platelets. furthermore, other
platelet  function  tests  like  born  aggregometry  or
platelet  function  analyzer  Pfa100™  (dade-behring,
Marburg, germany) require an adjustment of platelet
count on 100,000 ﾵl-1 or at least a platelet count above
100.000  ﾵl-1.  since  the  Multiplate™  device  analyses
platelet function in whole blood without adjustment
of platelet count it seems obvious that a marked de-
crease of platelet count results in a slower and less
dense occupation of sensor wires. this leads to a re-
duced aggregation velocity and maximum aggregation
as well. since the auc is dependent on both, velocity
and  maximum  aggregation,  a  decrease  of  platelet
count will also decrease auc.
our  results  show  that  measurements  using  com-
mercially available activators (coltest, adPtest, as-
PItest, tRaPtest) were all influenced by platelet count
in case of values below 150,000 ﾵl-1. of note, howev-
er, due to interindividual differences in platelet aggre-
gation, 44 % of all tested samples yielded normal re-
sults for platelet aggregation with the Multiplate™ de-
vice even in case of platelet counts of 100,000 ﾵl-1
and in 33% of blood samples with a platelet count of
50.000 ﾵl-1. on the other hand, 28 % of the blood
samples  yielded  an  auc  below  the  normal  Multi-
plate™  reference  range,  despite  a  normal  platelet
count. thus, results obtained by the Multiplate™ ana-
lyzer  are  dependend  on  both,  platelet  count  and
platelet function. 
In a peri-operative setting Multiplate™ analyzer is
used to assess overall platelet aggregability as a point-
of-care  method.  therefore,  auc  values  below  the
normal range in the presence of non-surgical bleeding
may be an indicator of decreased platelet aggregability
regardless of whether due to a low platelet count or
impaired platelet function [4, 22]. on the other hand,
normal  aggregation  values  as  shown  by  the  Multi-
plate™ device may avoid transfusion of platelets even
in the presence of a low platelet count. However, a
predictive value of results obtained from the Multi-
plate™  device  on  transfusion  requirements  was
demonstrated by Rahe-Meyer et al. in a clinical setting
during and after open heart surgery [13].
another purpose of the Multiplate™ analyzer is the
differentiation  of  effects  from  several  antiplatelet
drugs by analyzing different pathways of platelet acti-
vation.  nevertheless,  in  the  present  study  we  tested
untreated platelets only and thus did not test whether
the Mutiplate™ device can provide such information
in patients with a decreased platelet count. 
In conclusion, the results obtained with the Multi-
plate™ analyzer are dependent on platelet count and
function  with  decreased  aggregation  at  platelet  con-
centrations of 100.000 ﾵl-1 or below and Multiplate™
results are only dependent on platelet function in case
of platelet count is within the normal range.
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